News
NTEC
--
0.00%
--
GME, EDIT, QS and PSTI among midday movers
Gainers: Greenwich LifeSciences (GLSI) +424%.Xenetic Biosciences (XBIO) +329%.Rocket Pharmaceuticals (RCKT) +79%.MTS Systems (MTSC) +52%.Cypress Environmental Partners (CELP) +46%.Intec Pharma (NTEC) +42%.ZW Data Action Technologies (CNET) +33%.Cardtronics (CATM) +33%.Editas Medicine (EDIT) +27%.QuantumScape
Seekingalpha · 12/09/2020 17:39
Mid-Day Market Update: Dow Drops Over 100 Points; Rocket Pharmaceuticals Shares Jump
Midway through trading Wednesday, the Dow traded down 0.37% to 30,061.07 while the NASDAQ fell 0.28% to 12,546.99. The S&P also fell, dropping 0.28% to 3,691.99.
Benzinga · 12/09/2020 17:23
Xenetic Biosciences, Greenwich LifeSciences leads healthcare gainers; Atossa Therapeutics, Pluristem Therapeutics among major losers
Gainers: Xenetic Biosciences (XBIO) +410%, Greenwich LifeSciences (GLSI) +289%, Rocket Pharmaceuticals (RCKT) +74%, Intec Pharma (NTEC) +64%, ViewRay (VRAY) +14%.Losers: Atossa Therapeutics (ATOS) -39%, Pluristem Therapeutics (PSTI) -37%, Infinity Pharmaceuticals (INFI) -21%, Aytu BioScience (AYTU) -21%, Oncolytics Biotech (ONCY) -17%.
Seekingalpha · 12/09/2020 15:58
Mid-Morning Market Update: Markets Mixed; Campbell Soup Profit Tops Views
Following the market opening Wednesday, the Dow traded up 0.07% to 30,194.82 while the NASDAQ fell 0.10% to 12,570.09. The S&P also rose, gaining 0.06% to 3,704.53.
Benzinga · 12/09/2020 15:23
Thinking about buying stock in Rocket Pharmaceuticals, Sorrento Therapeutics, Intec Pharma, Cinedigm Corp, or Curis Inc?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RCKT, SRNE, NTEC, CIDM, and CRIS.
PR Newswire - PRF · 12/09/2020 13:30
Intec Pharma jumps 65% after research pact with UK based GW Pharma
Intec Pharma (NTEC) entered into a feasibility agreement with London based, GW Research to explore using the Accordion Pill ((AP)) platform for an undisclosed research program.The complete details of the agreement
Seekingalpha · 12/09/2020 12:20
Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma
Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec" or "the Company") today announces it has entered into a feasibility agreement with GW Research Limited ("GW"), London, U.K. to explore using the
Benzinga · 12/09/2020 12:07
Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma
, /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces it has entered into a feasibility agreement with GW Research Limited ("GW"), to explore using the Accordion Pill (AP) platform for an undisclosed research progr...
PR Newswire - PRF · 12/09/2020 12:00
Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces it has entered into a feasibility agreement with GW Research Limited ("GW"), London, U.K. to explore using the Accordion Pill (AP) platform for an undisclosed research program.
PR Newswire · 12/09/2020 12:00
CPE, FCEL, MACK and WKHS among midday movers
Gainers: NanoVibronix (NAOV) +99%.Merrimack Pharmaceuticals (MACK) +46%.Catabasis Pharmaceuticals (CATB) +44%.Tredegar (TG) +27%.Intec Pharma (NTEC) +27%.Kingsway Financial Services (KFS) +25%.Sequential Brands (SQBG) +23%.Sequans Communications (SQNS) +20%.Mmtec (MTC) +20%.Callon Petroleum (CPE) +20%.Losers: Ovid Therapeutics
Seekingalpha · 12/02/2020 17:41
Catabasis Pharmaceuticals, iBio leads healthcare gainers; Ovid Therapeutics, Auris Medical among major losers
Gainers: Catabasis Pharmaceuticals (CATB) +44%, iBio (IBIO) +21%, Cellectar Biosciences (CLRB) +21%, Intec Pharma (NTEC) +18%, Sio Gene Therapies (SIOX) +18%.Losers: Ovid Therapeutics (OVID) -55%, Auris Medical (EARS) -35%, iRhythm Technologies (IRTC) -20%, Medigus (MDGS) -18%, Altimmune (ALT) -17%.
Seekingalpha · 12/02/2020 16:04
Intec Pharma Granted European Patent Titled 'CARBIDOPA/LEVODOPA GASTRORETENTIVE DRUG DELIVERY'
https://data.epo.org/publication-server/pdf-document?pn=3115043&ki=B1&cc=EP
Benzinga · 11/25/2020 17:14
Precision Medicine Leader Dennis H. Langer, M.D., J.D. Joins Javelin Oncology's Board of Directors
, /PRNewswire/ -- Javelin Oncology, Inc. announced today that the company has named , M.D., J.D. to the company's board of directors as an independent director. Dr. Langer has served as a director of several public and private health care companies, and served in leadership roles in several pharmaceutical, biotechnology and diagnostic companies. Dr. Langer was a Senior Vice President at GlaxoSmithKline plc, served as CEO of Neose Technologies, Inc., and was President of Dr. Reddy's North American business. He is currently a director of Myriad Genetics, Inc., and was previously a director of Dicerna Pharmaceuticals, Inc. and Sirna Therapeutics, Inc.. Dr. Langer is a graduate of , and earned an M.D. at and a J.D. at Harvard Law School.
PR Newswire - PRF · 11/24/2020 13:17
Precision Medicine Leader Dennis H. Langer, M.D., J.D. Joins Javelin Oncology's Board of Directors
, /PRNewswire/ -- Javelin Oncology, Inc. announced today that the company has named , M.D., J.D. to the company's board of directors as an independent director. Dr. Langer has served as a director of several public and private health care companies, and s...
PR Newswire - PRF · 11/24/2020 13:17
Intec Pharma Reports Third Quarter 2020 Financial Results and Provides Corporate Update
, /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the third quarter ended and provides a corporate update. 
PR Newswire - PRF · 11/05/2020 12:00
Intec Pharma Reports Third Quarter 2020 Financial Results and Provides Corporate Update
, /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the third quarter ended and provides a corporate update. 
PR Newswire - PRF · 11/05/2020 12:00
Intec Pharma Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the third quarter ended September 30, 2020 and provides a corporate update.
PR Newswire · 11/05/2020 12:00
Intec Pharma Announces 1-for-20 Reverse Share Split
Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces a 1-for-20 reverse share split of its outstanding ordinary shares. The reverse share split is scheduled to become effective after trading closes on October 29, 2020, and the Compan...
PR Newswire · 10/29/2020 13:00
Intec Pharma Announces 1-for-20 Reverse Share Split
, /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces a 1-for-20 reverse share split of its outstanding ordinary shares. The reverse share split is scheduled to become effective after trading closes on , and the Com...
PR Newswire - PRF · 10/29/2020 12:00
Intec Pharma Announces 1-for-20 Reverse Share Split
, /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces a 1-for-20 reverse share split of its outstanding ordinary shares. The reverse share split is scheduled to become effective after trading closes on , and the Company's ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market at the commencement of trading on under the Company's existing symbol "NTEC." The Company's ordinary shares have been assigned a new CUSIP number of M53644148 in connection with the reverse share split. As previously disclosed, at the Company's Annual Meeting of Shareholders held on , the Company's shareholders approved a proposal to amend the Company's Articles of Association to effect a reverse share split of the Company's ordinary shares at a ratio with the range from 1-for-5 to 1-for-25, to be effective at the ratio and on a date to be determined by the Company's board of directors in its sole discretion.  
PR Newswire - PRF · 10/29/2020 12:00
Webull provides a variety of real-time NTEC stock news. You can receive the latest news about Intec Pharma through multiple platforms. This information may help you make smarter investment decisions.
About NTEC
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.
More